Understand the FDA cGMP 483 Analysis in One Article

    Abstract
The FDA483 report, also known as the on-site inspection report, is prepared by U.S. FDA inspectors following current U.S. laws and regulations after conducting on-site inspections of companies. It summarizes any non-compliances with cGMP requirements and is issued to the company. Companies are required to immediately address these non-compliance issues and, within 15 working days of receiving the 483 report, submit a response to the relevant FDA division detailing the corrective actions taken. If the FDA determines that the company’s response is appropriate and complies with applicable laws and regulations, the company will avoid receiving an FDA warning letter. Each fiscal year, the FDA compiles, summarizes, and publishes the 483 reports, making them available on its official website. This article provides a brief analysis of the 483 data released by the FDA from 2010 to 2015, with a particular focus on and brief analysis of FDA cGMP 483 reports. The aim is to offer pharmaceutical companies useful insights for improving their internal management systems.

    1 Data Overview

    1. Overview of 1483 Data
The FDA, whose full Chinese name is the Food and Drug Administration, oversees industries including food, various types of pharmaceuticals, and medical devices. Table 1 lists the summary results of inspections conducted across different sectors from fiscal years 2010 to 2015.
   

Table 1: The 483 documents issued from fiscal years 2010 to 2015

Note: *The above table does not represent all 483 documents issued during the fiscal year, as some of the 483 documents are handwritten and were not included in this table.
Looking at the 483 data across various sectors, food accounts for the largest share of 483, representing approximately half of the total. The proportion of pharmaceuticals within the 483 category ranged from 11.9% to 14.0% during the fiscal years from 2010 to 2015, with specific percentages being 11.9%, 10.5%, 12.3%, 13.2%, 12.7%, and 14.0%. Table 2 presents the quantity of pharmaceuticals included in the 483 category from fiscal years 2010 to 2015.

Table 2: Number of Pharmaceutical Products (483) for Fiscal Years 2010–2015

    2. Overview of Drug 483
Drug 483 pertains to the federal regulations and laws related to pharmaceuticals as outlined in Title 21 of the Code of Federal Regulations issued by the FDA, including Good Manufacturing Practices for Finished Pharmaceuticals, Good Manufacturing Practices for PET Pharmaceuticals, New Drugs, and the Federal Food, Drug, and Cosmetic Act. Table 3 lists the frequency of noncompliance occurrences for each regulation during fiscal years 2010–2015.

Table 3: Frequency of Nonconformities Found in Various Regulations from Fiscal Years 2010 to 2015

Among these, Part 211 of the 21 CFR sets forth the Current Good Manufacturing Practices for Finished Pharmaceuticals (effective date of the current version: April 1, 2014); Part 212 of the 21 CFR establishes the Current Good Manufacturing Practices for PET Pharmaceuticals (effective date of the current version: April 1, 2014); Part 310 of the 21 CFR covers New Drugs (effective date of the current version: April 1, 2014); Part 314 of the 21 CFR pertains to New Drug Applications for FDA Approval (effective date of the current version: April 1, 2014); Part 361 of the 21 CFR addresses prescription drugs deemed safe and effective and not bearing false or misleading labels: Investigational Drugs (effective date of the current version: April 1, 2014); FDCA 501: Federal Food, Drug, and Cosmetic Act Section 501; FDCA 503: Federal Food, Drug, and Cosmetic Act Section 503; FDCA 760: Federal Food, Drug, and Cosmetic Act Section 760.
As shown in Table 3, Section 211 of the 21 CFR received the highest frequency of 483 reports, accounting for 97.7%, 97.4%, 95.3%, 93.9%, 94.6%, and 96.7% of the total 483 reports for pharmaceutical products, respectively. Section 211 of the 21 CFR represents the U.S. FDA’s fundamental requirements for pharmaceutical manufacturing and serves as a key guideline that FDA inspectors rely on when auditing pharmaceutical companies.
    3. Overview of FDA cGMP 483 Data
FDA cGMP refers to Part 211 of the 21 CFR. Table 4 shows the distribution of nonconformities by the six major systems.

Table 4: Distribution of Pharmaceutical cGMP483 (Categorized by the Six Major Systems)

Table 4 shows that among the six major systems, the quality system had the highest number of nonconformities, accounting for approximately two-fifths of the total cGMP nonconformities. The laboratory testing system ranked second, representing about one-sixth of the total cGMP nonconformities. The facility and equipment system and the production system tied for third place, each accounting for roughly one-seventh of the total cGMP nonconformities.

    2 Six Major Systems, 483 Cases

    1. Status of Quality System 483
According to the data in Table 4, the proportion of quality system nonconformities relative to the total number of cGMP nonconformities was 40.8%, 40.6%, 40.4%, 37.2%, 37.2%, and 35.5% for the fiscal years 2010–2015, respectively, showing a year-on-year decrease. Table 5 summarizes some of the specific instances of defects found in the quality system.

Table 5: Summary of Nonconformities in the Quality System

There are numerous non-compliance issues in the quality management system, primarily manifested in an incomplete quality system—especially the documentation system—which lacks written quality management procedures or fails to fully comply with established procedures. These include QC/QA management procedures, employee training procedures, inbound inspection procedures, shipping procedures, and various types of records. Additionally, a lack of adequate personnel education, training, and practical experience is also a common deficiency.
The level of a pharmaceutical company’s quality system to some extent reflects the company’s quality culture. In fact, defects in quality systems are an international issue—such defects appear not only in FDA Form 483 reports but are also frequently reported in EudraGMDP non-compliance reports. Pharmaceutical companies should enhance their development of a strong quality culture, establish a comprehensive quality system, and regularly assess the effectiveness of their quality system’s operation.
    2. Laboratory Testing System 483
During the fiscal years 2010–2015, the probabilities of nonconformities in laboratory testing systems were 16.6%, 17.3%, 18.1%, 19.6%, 19.6%, and 19.4%, respectively. The following is a partial summary of nonconformities in laboratory testing systems.

Table 6: Summary of Nonconformities in the Laboratory Testing System

The main defects in laboratory testing systems are manifested in the failure to establish, insufficient adherence to, and untimely documentation of relevant procedures pertaining to quality standards, sampling plans, testing protocols, and laboratory control mechanisms—especially laboratory control procedures. These include ensuring the integrity, authenticity, and accuracy of laboratory data, which are frequent sources of non-compliance issues. Currently, the pharmaceutical industry is once again hotly debating the issue of data integrity (the CFDA has officially renamed it “data reliability”). Whether records are kept manually or electronically, integrity must remain the cornerstone. Pharmaceutical companies can ensure data integrity by strengthening the technical foundations for data and record management, refining record-keeping procedures, improving record documentation, implementing computerized system management, or providing high-quality employee training.
    3. Status of Factory Facilities and Equipment Systems 483
During the fiscal years 2010–2015, the probabilities of nonconformities in the plant facilities and equipment systems were 15.8%, 15.3%, 15.0%, 16.9%, 19.3%, and 20.0%, respectively. Table 7 provides a partial summary of nonconformities in the plant facilities and equipment systems.

Table 7: Summary of Nonconformities in Factory Facilities and Equipment Systems

In plant facilities and equipment systems, major deficiencies include inadequate prevention of cross-contamination, confusion, and errors; unreasonable design and layout that hinder operation, cleaning, and maintenance. It is also frequently found that automated equipment or instruments have not undergone accuracy verification, calibration, or control.
Cross-contamination is one of the three core principles of GMP. Pharmaceutical companies should thoroughly assess the feasibility of workshop layouts and conduct rigorous validation activities to avoid failing to meet regulatory requirements. Automated equipment, meanwhile, should be validated in accordance with applicable regulations, such as the latest GMP Appendix issued by the CFDA, specifically regarding computerized systems.
    4. Status of Production System 483
During the fiscal years 2010–2015, the probabilities of nonconformities in the production system were 15.2%, 14.5%, 15.1%, 15.9%, 15.2%, and 15.6%, respectively. The following is a partial list of these production system nonconformities.

Table 8: Summary of Nonconformities in the Production System

The common non-compliance issues in production systems mainly include the absence of written procedures for production and process control, as well as for microbial contamination control; failure to follow written procedures; untimely documentation; failure to calculate yields at each step; and failure to perform sterilization process validation. It is worth noting that domestic pharmaceutical companies often overlook pyrogen removal process validation, which would be considered a serious deficiency during FDA certification. Process validation should be conducted in accordance with the methods outlined in the 2011 FDA Industry Guidance—General Principles and Guidelines for Process Validation—and must cover the entire lifecycle of a drug, from the drug development stage all the way through product withdrawal from the market.
    5. Status of Material System 483
During the fiscal years 2010–2015, the probabilities of nonconformities in the material system were 7.0%, 7.1%, 7.2%, 6.7%, 5.5%, and 6.4%, respectively. The following is a partial list of nonconformities in the material system.

Table 9: Summary of Nonconformities in the Material System

The primary causes of non-compliance in the material management system are insufficient written procedures and excessive reliance on supplier inspection reports without conducting independent inspections. Strictly speaking, the defects listed in Table 9 are part of the quality system itself. This underscores the need for pharmaceutical companies to enhance their quality awareness and rigorously control the quality of drug production at every stage.
    6. Packaging and Labeling System 483 Status
During fiscal years 2010–2015, the probabilities of nonconformities in the packaging and labeling systems were 4.7%, 5.3%, 4.2%, 3.8%, 3.0%, and 3.1%, respectively. Table 10 summarizes some of the specific instances of nonconformities in the packaging and labeling systems.

Table 10: Summary of Nonconformities in the Packaging and Labeling System

There are still instances in the packaging and labeling system where procedures are either not documented or not fully followed. Moreover, the determination of expiration dates lacks scientific rigor. Similarly, defects in the packaging and labeling system to some extent also reflect shortcomings in the quality management system.
    3 Conclusion
As the capabilities of domestic pharmaceutical companies continue to improve, many enterprises are eager to enter the European and U.S. markets. Obtaining FDA cGMP certification represents the minimum threshold for entry into these markets. The information provided in this article is intended solely as a reference for pharmaceutical companies to assess whether their existing quality assurance systems comply with FDA cGMP requirements. In particular, regarding the documentation, completeness, and thorough adherence to procedures—in both quality systems and packaging and labeling systems—any instances of non-compliance should prompt deep reflection and heightened vigilance among pharmaceutical companies.